Abstract BACKGROUND: Prospective studies on insulin-like growth factor I (IGF-I) and epithelial ovarian cancer (EOC) risk are inconclusive. Data suggest risk associations vary by tumour characteristics. METHODS: We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) to evaluate IGF-I concentrations and EOC risk by tumour characteristics (n=565 cases). Multivariable conditional logistic regression models were used to estimate associations. RESULTS: We observed no association between IGF-I and EOC overall or by tumour characteristics. CONCLUSIONS: In the largest prospective study to date was no association between IGF-I and EOC risk. Pre-diagnostic serum IGF-I concentrations may not influence EOC risk.

Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: Results from the EPIC cohort

POPOVIC, MAJA;
2015-01-01

Abstract

Abstract BACKGROUND: Prospective studies on insulin-like growth factor I (IGF-I) and epithelial ovarian cancer (EOC) risk are inconclusive. Data suggest risk associations vary by tumour characteristics. METHODS: We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) to evaluate IGF-I concentrations and EOC risk by tumour characteristics (n=565 cases). Multivariable conditional logistic regression models were used to estimate associations. RESULTS: We observed no association between IGF-I and EOC overall or by tumour characteristics. CONCLUSIONS: In the largest prospective study to date was no association between IGF-I and EOC risk. Pre-diagnostic serum IGF-I concentrations may not influence EOC risk.
2015
112
1
162
166
http://www.nature.com/bjc/index.html
carcinogenesis; dualistic pathway; histological subtypes; IGF-I; ovarian cancer; type I/type II; Adult; Aged; Case-Control Studies; Cohort Studies; Europe; Female; Humans; Insulin-Like Growth Factor I; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Risk; Oncology; Cancer Research
Ose, J; Fortner, R.T.; Schock, H.; Peeters, P.H.; Onland-Moret, N.C.; Bueno-De-Mesquita, H.B.; Weiderpass, E.; Gram, I.T.; Overvad, K.; Tjonneland, A.; Dossus, L.; Fournier, A.; Baglietto, L.; Trichopoulou, A.; Benetou, V.; Trichopoulos, D.; Boeing, H.; Masala, G.; Krogh, V.; Matiello, A.; Tumino, R.; Popovic, M.; Obón-Santacana, M.; Larraã±aga, N.; Ardanaz, E.; Sã¡nchez, M.-J.; Menã©ndez, V.; Chirlaque, M.-D.; Travis, R.C.; Khaw, K.-T.; Brã¤ndstedt, J.; Idahl, A.; Lundin, E.; Rinaldi, S.; Kuhn, E.; Romieu, I.; Gunter, M.J.; Merritt, M.A.; Riboli, E.; Kaaks, R.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1647557
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 15
social impact